Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,733 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rosuvastatin combined with regular exercise preserves coenzyme Q10 levels associated with a significant increase in high-density lipoprotein cholesterol in patients with coronary artery disease.
Toyama K, Sugiyama S, Oka H, Iwasaki Y, Sumida H, Tanaka T, Tayama S, Jinnouchi H, Matsui K, Ogawa H. Toyama K, et al. Among authors: oka h. Atherosclerosis. 2011 Jul;217(1):158-64. doi: 10.1016/j.atherosclerosis.2011.02.050. Epub 2011 Mar 10. Atherosclerosis. 2011. PMID: 21458815 Clinical Trial.
Impact of candesartan on cardiovascular events after drug-eluting stent implantation in patients with coronary artery disease: The 4C trial.
Sakamoto T, Ogawa H, Nakao K, Hokimoto S, Tsujita K, Koide S, Yamamoto N, Shimomura H, Matsumura T, Oshima S, Kikuta K, Oka H, Kimura K, Matsui K; 4C (Candesartan for Prevention of Cardiovascular Events after CYPHER™ or TAXUS™ Coronary Stenting) study investigators. Sakamoto T, et al. Among authors: oka h. J Cardiol. 2016 Apr;67(4):371-7. doi: 10.1016/j.jjcc.2015.06.009. Epub 2015 Aug 4. J Cardiol. 2016. PMID: 26254019 Free article. Clinical Trial.
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial.
Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K, Komura N, Sakamoto K, Oka H, Nakao K, Nakamura S, Ishihara M, Matsui K, Sakaino N, Nakamura N, Yamamoto N, Koide S, Matsumura T, Fujimoto K, Tsunoda R, Morikami Y, Matsuyama K, Oshima S, Kaikita K, Hokimoto S, Ogawa H; PRECISE–IVUS Investigators. Tsujita K, et al. Among authors: oka h. J Am Coll Cardiol. 2015 Aug 4;66(5):495-507. doi: 10.1016/j.jacc.2015.05.065. J Am Coll Cardiol. 2015. PMID: 26227186 Free article. Clinical Trial.
Clinical outcomes of percutaneous coronary intervention (PCI) at hospital with or without onsite cardiac surgery backup.
Akasaka T, Hokimoto S, Oshima S, Nakao K, Fujimoto K, Miyao Y, Shimomura H, Tsunoda R, Hirose T, Kajiwara I, Matsumura T, Nakamura N, Yamamoto N, Koide S, Oka H, Morikami Y, Sakaino N, Kaikita K, Nakamura S, Matsui K, Ogawa H; Kumamoto Intervention Conference Study (KICS) Investigators. Akasaka T, et al. Among authors: oka h. Int J Cardiol. 2014 Oct 20;176(3):1385-7. doi: 10.1016/j.ijcard.2014.08.027. Epub 2014 Aug 10. Int J Cardiol. 2014. PMID: 25156861 No abstract available.
Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE-IVUS Trial): Study protocol for a randomized controlled trial.
Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K, Komura N, Sakamoto K, Ono T, Oka H, Nakao K, Nakamura S, Ishihara M, Matsui K, Sakaino N, Nakamura N, Yamamoto N, Koide S, Matsumura T, Fujimoto K, Tsunoda R, Morikami Y, Matsuyama K, Oshima S, Kaikita K, Hokimoto S, Ogawa H; PRECISE-IVUS study investigators. Tsujita K, et al. Among authors: oka h. J Cardiol. 2015 Oct;66(4):353-8. doi: 10.1016/j.jjcc.2014.12.011. Epub 2015 Jan 7. J Cardiol. 2015. PMID: 25577723 Free article. Clinical Trial.
1,733 results